Amylyx Pharmaceuticals, Inc. (AMLX)
- Previous Close
1.8800 - Open
1.8700 - Bid 1.7200 x 700
- Ask 1.7900 x 1600
- Day's Range
1.7600 - 1.9100 - 52 Week Range
1.7600 - 30.5000 - Volume
2,466,609 - Avg. Volume
3,306,179 - Market Cap (intraday)
121.05M - Beta (5Y Monthly) -0.93
- PE Ratio (TTM)
2.54 - EPS (TTM)
0.7000 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
amylyx.comRecent News: AMLX
Performance Overview: AMLX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AMLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AMLX
Valuation Measures
Market Cap
121.05M
Enterprise Value
-246.07M
Trailing P/E
2.54
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.33
Price/Book (mrq)
0.28
Enterprise Value/Revenue
-0.65
Enterprise Value/EBITDA
-6.17
Financial Highlights
Profitability and Income Statement
Profit Margin
12.94%
Return on Assets (ttm)
5.34%
Return on Equity (ttm)
12.73%
Revenue (ttm)
380.79M
Net Income Avi to Common (ttm)
49.27M
Diluted EPS (ttm)
0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
371.36M
Total Debt/Equity (mrq)
0.98%
Levered Free Cash Flow (ttm)
38.36M
Research Analysis: AMLX
Company Insights: AMLX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: AMLX
Daily – Vickers Top Buyers & Sellers for 04/03/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/30/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/24/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 03/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.